220 related articles for article (PubMed ID: 16607930)
21. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
Lim JS; Jin SH; Kim SB; Lee JI
J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
[TBL] [Abstract][Full Text] [Related]
22. Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates.
Zacharin M; Cundy T
J Pediatr; 2000 Sep; 137(3):410-5. PubMed ID: 10969269
[TBL] [Abstract][Full Text] [Related]
23. The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
Anagnostis P; Vyzantiadis TA; Charizopoulou M; Adamidou F; Karras S; Goulis DG; Karagiannis A; Garipidou V; Vakalopoulou S
Thromb Haemost; 2013 Aug; 110(2):257-63. PubMed ID: 23740140
[TBL] [Abstract][Full Text] [Related]
24. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
25. Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.
Baroncelli GI; Vierucci F; Bertelloni S; Erba P; Zampollo E; Giuca MR
J Bone Miner Metab; 2013 Sep; 31(5):533-43. PubMed ID: 23549954
[TBL] [Abstract][Full Text] [Related]
26. Clinical Response to Treatment with Teriparatide in an Adolescent with Osteoporosis-Pseudoglioma Syndrome (OPPG): A Case Report.
Homaei A; Chegini V; Saffari F
Int J Endocrinol Metab; 2022 Apr; 20(2):e121031. PubMed ID: 35993038
[TBL] [Abstract][Full Text] [Related]
27. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
[TBL] [Abstract][Full Text] [Related]
28. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
Gallacher SJ; Fenner JA; Anderson K; Bryden FM; Banham SW; Logue FC; Cowan RA; Boyle IT
Thorax; 1992 Nov; 47(11):932-6. PubMed ID: 1465751
[TBL] [Abstract][Full Text] [Related]
29. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions.
Steelman J; Zeitler P
J Pediatr; 2003 Apr; 142(4):417-23. PubMed ID: 12712060
[TBL] [Abstract][Full Text] [Related]
30. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
31. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
[TBL] [Abstract][Full Text] [Related]
32. Intravenous pamidronate in the treatment and prevention of osteoporosis.
Chan SS; Nery LM; McElduff A; Wilmshurst EG; Fulcher GR; Robinson BG; Stiel JN; Gunton JE; Clifton-Bligh PB
Intern Med J; 2004 Apr; 34(4):162-6. PubMed ID: 15086695
[TBL] [Abstract][Full Text] [Related]
33. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits.
Leung TF; Chu Y; Lee V; Cheng FW; Leung WK; Shing MM; Li CK
Hemoglobin; 2009; 33(5):361-9. PubMed ID: 19814683
[TBL] [Abstract][Full Text] [Related]
35. Effect of single dose intravenous zoledronic acid on bone mineral density in post-menopausal osteoporosis of Bangladeshi women.
Hossain M; Chowdhury IH; Emran MA; Habib AH; Asaduzzamnan AK; Alam M; Ferdous C
Bangladesh Med Res Counc Bull; 2010 Dec; 36(3):74-7. PubMed ID: 21548542
[TBL] [Abstract][Full Text] [Related]
36. Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome.
Vujasinovic-Stupar N; Pejnovic N; Markovic L; Zlatanovic M
Rheumatol Int; 2012 Mar; 32(3):819-23. PubMed ID: 21327429
[TBL] [Abstract][Full Text] [Related]
37. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
Torregrosa JV; Fuster D; Monegal A; Gentil MA; Bravo J; Guirado L; Muxí A; Cubero J
Osteoporos Int; 2011 Jan; 22(1):281-7. PubMed ID: 20229199
[TBL] [Abstract][Full Text] [Related]
39. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis.
Fromm GA; Vega E; Plantalech L; Galich AM; Mautalen CA
Osteoporos Int; 1991 Jun; 1(3):129-33. PubMed ID: 1790400
[TBL] [Abstract][Full Text] [Related]
40. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.
Orr-Walker B; Wattie DJ; Evans MC; Reid IR
Clin Endocrinol (Oxf); 1997 Jan; 46(1):87-92. PubMed ID: 9059563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
